Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 2/20 | 0.41 |
| ▸ | FOLH1 | Q04609 | 6/20 | 0.40 |
| ▸ | CPB2 | Q96IY4 | 3/20 | 0.40 |
| ▸ | MMP2 | P08253 | 1/20 | 0.39 |
| ▸ | MMP9 | P14780 | 1/20 | 0.39 |
| ▸ | MMP8 | P22894 | 1/20 | 0.39 |
| ▸ | MMP13 | P45452 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.38 |
| ▸ | ITGA5 | P08648 | 1/20 | 0.38 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.37 |
| ▸ | ACE | P12821 | 2/20 | 0.37 |
| ▸ | MME | P08473 | 1/20 | 0.37 |
| ▸ | CPA1 | P15085 | 1/20 | 0.37 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31754250 | 0.83 | TSHR (0.46) | PPARGFOLH1CPB2ITGB1ITGA5 | |
| SCHEMBL31688466 | 0.82 | CPB2 (0.59) | CPB2CPA1 | |
| SCHEMBL31369973 | 0.82 | CPB2 (0.59) | CPB2CPA1 | |
| SCHEMBL22444704 | 0.79 | KLKB1 (0.48) | PPARGALDH1A1ITGB1ITGA5 | |
| SCHEMBL21838062 | 0.79 | PPARG (0.42) | PPARGCPB2ITGB1ITGA5 | |
| SCHEMBL25356796 | 0.79 | KLKB1 (0.48) | PPARGALDH1A1ITGB1ITGA5 | |
| SCHEMBL29633767 | 0.79 | KLKB1 (0.48) | PPARGALDH1A1ITGB1ITGA5 | |
| SCHEMBL21838059 | 0.79 | PPARG (0.42) | PPARGCPB2ITGB1ITGA5 | |
| SCHEMBL30861843 | 0.79 | PPARG (0.42) | PPARGCPB2ITGB1ITGA5 | |
| SCHEMBL805199 | 0.79 | ALDH1A1 (0.56) | PPARGFOLH1ALDH1A1ACEMME |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260001914-A1 | MACROCYCLIC PEPTIDES TARGETING KRAS | MERCK SHARP & DOHME LLC (US) | 2026-01-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260001914-A1 | MACROCYCLIC PEPTIDES TARGETING KRAS | KRAS, NRAS, HRAS | PPARG 2133/4885FOLH1 1038/4885CPB2 2599/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.